First on OpenAIRE

H63D Syndrome Research Consortium

Ali Shirazi, Riku Honda, Fabio Rocha, Olga Ivanova, Miriam Schneider, Alexander Bartels, Marianne Kaufmann, Peter Müller, Sofia Makri, Boris Dimitrikov, Carolina Diamandis
Correspondence to team@h63d.org

Keywords:
Oshtoran Syndrome, PANS, H63D Syndrome Type-3, HFE gene, iron metabolism, micro-inflammation, neuropsychiatric issues, mitochondriopathy, organ damage, autonomic dysfunction

Neuroendocrinology

Oshtoran Syndrome H63D Syndrome Type-3

Abstract

Oshtoran Syndrome, also known as H63D Syndrome Type-3, is a multifaceted meta-syndromic condition characterized by an array of clinical manifestations. These manifestations include irregular iron homeostasis, micro-inflammatory events, neuropsychiatric disturbances, multi-organ pathology, and notably, autonomic dysfunctions that affect the Central Nervous System, the Autonomous Nervous System, and the innate immune system. A nuanced understanding of the underlying pathophysiological mechanisms is crucial for precise diagnosis, evidence-based management, and the development of targeted therapeutic strategies. Healthcare professionals are encouraged to employ an interdisciplinary framework in patient management, accentuating the imperative for early diagnostic efforts, timely interventions, and patient-focused educational initiatives. Future research should strategically focus on the employment of gene-editing technologies and the identification of novel therapeutic options to address the root genetic anomalies and the corresponding heterogeneous symptomatology.

Introduction

The Oshtoran Syndrome, a newly identified medical phenomenon, represents a turning point in both clinical medicine and international scientific collaboration. Initially identified by two separate research groups—one led by Dr. Adams and the other by Dr. Zafarian—a shared interest in this novel pathological entity united these teams despite differing geopolitical landscapes and resources. The academic community now faces a unique opportunity to expand the clinical understanding of this syndrome through the International H63D Mutation Syndrome Research Consortium, a politically neutral and scientifically reputable organization. The Consortium's survey among clinical professionals worldwide revealed that the condition is far more common than previously estimated, emphasizing the necessity for rigorous scientific inquiry. This paper serves as a guideline for future research, presenting an integrated framework built upon the existing research efforts of Dr. Adams' and Dr. Zafarian's teams. This includes critical scrutiny of diagnostic criteria, a detailed depiction of methodological approaches, and a blueprint for future research endeavors. Particular focus is given to adhering to strict scientific principles and avoiding any political influence, as mandated by the H63D Consortium's guidelines.[21-26]

Diagnostic path

Oshtoran Syndrome is one of the few meta-syndromes in the strict sense of accuracy. But what is a meta-syndrom? A Meta-Syndrome refers to a highly complex and multifaceted medical condition that transcends the boundaries of individual syndromes or diseases, manifesting as a conglomeration of diverse symptoms, pathologies, and etiological factors. Unlike singular syndromes characterized by a fairly distinct set of symptoms and often an identifiable underlying pathology, meta-syndromes present an intricate labyrinth of interrelated and often overlapping clinical features. This complexity frequently involves multiple physiological systems, including but not strictly limited to neurological, immunological, metabolic, and hematological domains.[31,39,44,45,46] Within a meta-syndrome, disparate symptoms may not only co-occur but can also engage in dynamic interactions, thus amplifying, mitigating, or otherwise modulating each other's impact. This brings forth substantial challenges in the realm of diagnostics. The conventional diagnostic models, which often rely on well-defined criteria and diagnostic markers, may be inadequate or even misleading when faced with the multi-systemic and multifactorial nature of meta-syndromes. The diagnostic process may require a battery of sophisticated tests involving next-generation sequencing, comprehensive metabolic panels, advanced imaging modalities, and occasionally, exploratory procedures to uncover less-apparent symptoms or underlying pathologies. Moreover, the polygenic or epigenetic factors that frequently underlie these meta-syndromes necessitate a more expansive approach to genetic screening and counseling.

Importantly, the diagnostic imprecision often associated with meta-syndromes has several downstream implications: it can delay targeted therapeutic interventions, create prognostic uncertainty, and

complicate treatment paradigms, which often have to be multimodal and dynamically adaptable to account for the syndromic interplay. Furthermore, the often elusive nature of meta-syndromes mandates a continual reassessment of the diagnostic criteria, making it a moving target that challenges the rigidity of conventional medical algorithms. It becomes crucial, then, for clinicians to adopt an interdisciplinary approach that integrates insights from various specialties, as the traditional siloed approach is ill-suited for the diagnostic complexities posed by meta-syndromes. Therefore, understanding meta-syndromes calls for a paradigmatic shift in the diagnostic methodologies, compelling the medical community to evolve more holistic and dynamically adaptable models for diagnosis and treatment.[44,45,46]

Oshtoran Syndrome fulfills the criteria for classification as a meta-syndrome owing to its intricate, multi-systemic, and dynamically interactive symptomatology, which defies the linear and often isolated manifestations characteristic of more conventional syndromes. One of the hallmark features of a meta-syndrome is the intricate involvement of multiple physiological systems, and Oshtoran Syndrome is no exception.[25] It prominently displays symptoms that cut across various domains—neurological, hematological, and immunological, to name a few. These symptoms, such as aberrant iron metabolism, neuropsychiatric disturbances, and autonomic dysfunctions, do not exist in isolation but rather engage in a complex interplay that impacts the individual's overall health status. Furthermore, Oshtoran Syndrome's multifactorial etiology involves both genetic mutations, possibly polygenic in nature, and epigenetic modifications, thus meeting another criterion of a meta-syndrome. The complexity of its genetic underpinning requires extensive molecular diagnostic approaches that go beyond the scope of monogenic tests, further necessitating the employment of more sophisticated, genome-wide assays. Another reason for its classification as a meta-syndrome lies in its diagnostic complexity. The heterogeneity of its presentation makes it resistant to classification by any single set of diagnostic criteria or biomarkers. Therefore, clinicians often find themselves utilizing a plethora of diagnostic tools ranging from advanced imaging modalities to comprehensive metabolic panels and even exploratory procedures, a characteristic diagnostic challenge associated with meta-syndromes. The variable course of the syndrome, often punctuated by periods of symptom exacerbation and quiescence, further exemplifies its meta-syndromic nature. This dynamism is not just temporal but can also be situational, influenced by external factors like stress or infection, thereby requiring a diagnostic approach that is equally dynamic and adaptable.

Additionally, the management of Oshtoran Syndrome inherently calls for a multidisciplinary approach, reflecting yet another meta-syndromic trait. Given the broad spectrum of symptoms, treatment paradigms must encompass pharmacological, psychological, and lifestyle interventions that are often customized and adjusted in real-time according to the patient's response. In conclusion, the multi-systemic involvement, complex genetic etiology, diagnostic intricacy, and the requirement for an interdisciplinary treatment approach collectively argue for the classification of Oshtoran Syndrome as a meta-syndrome. This complexity not only mandates a nuanced understanding of its pathophysiology but also necessitates a

paradigmatic shift in diagnostic and treatment protocols, aligning closely with the challenges posed by meta-syndromes in general.[23,24,25,26]

What is Oshtoran Syndrome?

Oshtoran Syndrome represents a quintessential example of a cascading-progredient meta-syndrome, characterized by an intricate, multi-layered pathology that evolves over time and becomes increasingly complex. The syndrome is rooted in specific genetic vulnerabilities, namely a homozygous mutation of the HFE gene (H63D) and a predisposing genetic trait for pyruvate dehydrogenase complex dysfunction. Vulnerabilities like these may serve as a primordial ground for the development of PANS syndrome during childhood or adolescence. Should PANS develop and persist into adulthood, individuals with these specific genetic predispositions face escalating risks. The H63D mutation contributes to an overload of Non-Transferrin Bound Iron (NTBI), a condition that fosters oxidative damage in critical tissues like the substantia nigra and basal ganglia. Importantly, this NTBI-induced damage is elusive, defying detection through standard diagnostic modalities such as MRI, CT scans, and biopsies. Concurrently, the dormant predisposition to mitochondrial dysfunction activates, shifting the cellular metabolism from an aerobic to an anaerobic state. This metabolic shift exacerbates tissue damage and may potentiate the effects of NTBI overload, spiraling the individual into a state of systemic dysfunction. As the syndrome advances, it culminates in autonomic dysregulation, affecting not only the autonomous nervous system but also extending its deleterious effects to the central nervous system and the innate immune system. This autonomic dysregulation further misguides organ function through faulty innervation, thereby adding an additional layer of complexity to an already convoluted clinical picture. As such, Oshtoran Syndrome encapsulates the essence of a cascading-progredient meta-syndrome, requiring a nuanced, dynamic, and multidisciplinary approach for its diagnosis and management, given its deeply interconnected and perpetually evolving pathophysiology. The perilous nature of Oshtoran Syndrome cannot be overstated, particularly given its cascading-progredient and meta-syndromic characteristics. Each stage of the syndrome not only amplifies existing complications but also introduces new, potentially irreversible, pathologies. For example, the NTBI overload initially causes subtle but widespread oxidative damage that eludes early detection, setting the stage for insidious organ dysfunction. As these tissues succumb to oxidative stress, the possibility of permanent, potentially fatal organ failure becomes increasingly likely. The activated mitochondrial dysfunction further complicates the clinical picture, weakening cellular metabolism and exacerbating the body's already compromised ability to repair and regenerate tissue.[48,49,50,51,52,53]

This, in turn, creates a fertile ground for systemic inflammation, mostly oxidative micro-inflammations, enhancing the risk of further organ damage and even more severe dysfunctions, including sudden and unexpected life-threatening situations. Perhaps most insidiously, the autonomic dysregulation introduces a layer of complexity that poses its own unique dangers.[13,19,21,27,39-34,46,48-52] By disrupting the regulatory mechanisms of the autonomous and central nervous systems, as well as the innate immune system, Oshtoran Syndrome derails the body's innate ability to maintain homeostasis. This

dysregulation can manifest in a variety of catastrophic ways, from cardiovascular instability to impaired thermoregulation and disordered immune responses, heightening the risk of secondary infections, and autoimmunity. Furthermore, the syndrome's progressively worsening nature makes timely and effective intervention increasingly challenging. As multiple systems become compromised, the therapeutic window narrows, rendering conventional treatments less effective and elevating the risk of severely adverse drug interactions or contraindications. In essence, Oshtoran Syndrome is a ticking time bomb of complex, interrelated pathologies that progressively deteriorate the patient's health, making it a medical emergency that demands immediate, aggressive, and multifaceted intervention. Failure to slow down its progression can result in catastrophic outcomes, ranging from permanent organ damage to systemic failure.[12,13,14,15-36]

Research

The imperative for comprehensive research into Oshtoran Syndrome is underscored by its multi-systemic, cascading-progredient nature and the serious, often life-threatening, ramifications it presents. As a meta-syndrome, Oshtoran poses a uniquely convoluted set of diagnostic and therapeutic challenges. It originates from a nuanced insidious interplay of genetic predispositions, namely the HFE gene (H63D) and traits that predispose to mitochondrial dysfunction, which together pave the way for a gamut of pathologies ranging from NTBI overload to autonomic dysregulation. Each of these elements introduces its own complexities and eludes straightforward clinical assessment, often going undetected by conventional diagnostic modalities like MRI and CT scans. Moreover, the syndrome evolves in a cascading manner, exponentially amplifying the risks and complications as it progresses. Each stage not only intensifies the existing pathologies but also activates new, interconnected problems, leading to an increasingly refractory and deteriorating clinical state. In essence, Oshtoran Syndrome is a labyrinthine construct of medical challenges that defy compartmentalization into single-system diseases or conditions. Its very nature necessitates an integrated, interdisciplinary approach to both research and clinical management. Traditional single-target therapies are not merely inadequate; they risk being counterproductive by not addressing the syndrome's overarching, interconnected pathology. The lack of a unifying diagnostic criteria or gold-standard treatment protocol makes it an urgent subject for in-depth research. It is paramount that research focuses on identifying early biomarkers, elucidating the mechanisms underlying its multi-systemic impact, and developing targeted, synergistic therapeutic interventions capable of halting or reversing the syndrome's cascading progression. Failing to advance our understanding of Oshtoran Syndrome will result in continued clinical impasses, worsening patient outcomes, and an inevitable rise in healthcare burden due to its complex and severe nature.[23,24,25,26]

Therapeutic Approaches and Future Research

Certainly, it is crucial to emphasize that iron chelation is absolutely contraindicated in Oshtoran Syndrome patients who exhibit low ferritin levels, as this would exacerbate the already precarious metabolic imbalance and could be life-threatening. At this juncture, the primary mode of therapeutic

intervention for Oshtoran Syndrome is a broad anti-inflammatory approach.[47] The Tryptophan/Kynurenine ratio serves as the only sufficiently sensitive parameter to guide this treatment, as other conventional markers lack the sensitivity to capture the syndrome's complex pathology accurately.[29] Furthermore, additional therapeutic strategies aim to modulate and control hyperactive stress response systems. Effective management should include measures to reduce and regulate elevated levels of stress hormones such as adrenaline, cortisol, and most critically, noradrenaline. Targeting the endocrine stress system and the innate immune system is also of paramount importance. Collectively, these approaches aim to bring at least some semblance of regulatory control back to the disordered autonomic and immune systems, thereby mitigating the downstream cascading effects that contribute to the syndrome's progression.[47]

Oshtoran Syndrome and Multiple System Atrophy (MSA)

Another rare disease, Multiple System Atrophy (MSA), may superficially appear analogous, given their multi-systemic nature and their ability to affect a diverse range of organ systems including the autonomic nervous system. However, it is crucial to delineate the stark differences in their pathogenesis and prognosis. While Multiple System Atrophy is a neurodegenerative disease with a bleak prognosis and no curative treatments, ultimately resulting in fatality, Oshtoran Syndrome presents a contrasting picture. Rooted in a complex interplay of genetic mutations and metabolic imbalances, notably involving the HFE gene (H63D)[10,11,12,13,14,15] and the so called pyruvate dehydrogenase complex dysfunction[48,49,50,51,52,53], Oshtoran Syndrome is the perfect prototype of a meta-syndrome characterized by cascading systemic failures but with a markedly different trajectory. With vigilant management, particularly involving a broad anti-inflammatory approach and meticulous endocrine and autonomic modulation, patients with Oshtoran Syndrome have the potential to achieve a normal life span. They do, however, tread on precarious ground, given the syndrome's dynamic and complex nature, and live what could be metaphorically termed 'a life on thin ice.' Both conditions present with autonomic dysfunctions, among other symptoms, but the parallel ends there. MSA follows an invariably progressive course leading to multiple organ failures and ultimately, death. In contrast, Oshtoran Syndrome, though complex and challenging, offers windows of therapeutic intervention that can not only ameliorate symptoms but potentially halt or even reverse some of the cascading systemic dysfunctions. Hence, while both syndromes are multi-systemic and manifest a variety of overlapping symptoms, they are fundamentally different in their pathogenesis, treatment options, and most critically, in their long-term outcomes.[54]

Therapy

Further research into Oshtoran Syndrome is anticipated to span several years, largely attributable to the pharmaceutical industry's limited interest. This timeline is palpably inadequate for patients currently afflicted by the syndrome. Consequently, we at the International H63D Mutation Syndrome Consortium have established an interdisciplinary and international task force to formulate provisional proposals for pharmacological, interventions.[47] These recommendations draw upon an extensive

database and insights from our global network of best-practice affiliates. Oshtoran Syndrome, despite its complex etiological history, is unequivocally a severe disease with well-defined, systemic, and organic ramifications. Choosing not to intervene due to the absence of peer-reviewed studies in high-impact journals constitutes an ethical lapse in medical judgment. Any licensed medical professional ought to be capable of diagnosing and treating diseases based on foundational knowledge in biology and chemistry, even in the absence of comprehensive research. Evasion of such ethical obligations constitutes malpractice. Based on these considerations, a tripartite model of treatment is recommended as of 2023:[47]

1. Upon detecting chronically elevated levels of inflammation—evidenced, for instance, by the tryptophan/kynurenine ratio—a broad-spectrum, potent anti-inflammatory regimen is warranted. This is not yet a formal guideline, hence the choice of anti-inflammatory agents remains at the discretion of the treating physician. Traditional interventions like corticosteroids may be advisable, given their broad-spectrum efficacy, although they necessitate frequent reassessment due to associated risks.
2. Preliminary studies conducted within consortium-affiliated laboratories, as well as clinical reports, indicate that influencing the production, regulation, and breakdown of catecholamines and cortisone may mitigate the risk of cascading, life-threatening dysregulation in autonomic, central nervous, and innate immune systems. Off-label agents, substantiated by studies such as those by Breier et al. (1992), may be employed cautiously. Medications like doxazosin, non-cardioselective beta-blockers such as propranolol, and noradrenaline modulators like tramadol may be valuable adjuncts. Synergistic benefits may arise from innovative combinations of older medications, necessitating collaboration with pharmacists.
3. Additional, symptom-specific interventions will be tailored to individual patient profiles.

Patients with Oshtoran Syndrome should not be confined to fixed, calendar-based follow-ups; immediate consultation should be available in cases of symptom exacerbation. Misattributing symptoms to psychosomatic origins represents another form of malpractice. In severe H63D syndrome cases, maintaining a transferrin saturation value below 45% is critical. Chelation therapies are contraindicated in the presence of normal or low ferritin levels. Healthcare providers must acknowledge the dual challenges of treating an inadequately researched disease that holds the potential for rapid destabilization. An open, robust doctor-patient relationship is crucial for mutual protection and effective treatment.

Conclusion

Oshtoran Syndrome, also known as H63D Syndrome Type-3 or PANS-H63D-Multisystemic Instability Syndrome, is a complex clinical entity causing significant pathophysiological disturbances in those affected. Given the paucity of robust empirical data, further research is essential to establish patient-centric, individualized therapeutic strategies. Importantly, the ongoing nature of current research should not preclude immediate interventions aimed at ameliorating symptoms, extending life expectancy, or even effecting life-saving measures for individuals currently suffering from the syndrome.

Warning

The treatment strategies delineated in this paper are strictly experimental and are to be undertaken at one's own risk; the authors categorically disclaim all responsibility for any consequences arising from the implementation of these recommendations.

Conflicts of interest

None declared.

References

1. Feder, J. N., Gnirke, A., Thomas, W., Tsuchihashi, Z., Ruddy, D. A., Basava, A., et al. (1996). A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nature Genetics, 13(4), 399-408.
2. Hanson, E. H., Imperatore, G., & Burke, W. (2001). HFE gene and hereditary hemochromatosis: a HuGE review. American Journal of Epidemiology, 154(3), 193-206.
3. Ganz, T. (2003). Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood, 102(3), 783-788.
4. Camaschella, C. (2015). Iron-deficiency anemia. New England Journal of Medicine, 372(19), 1832-1843.
5. Valko, M., Leibfritz, D., Moncol, J., Cronin, M. T., Mazur, M., & Telser, J. (2007). Free radicals and antioxidants in normal physiological functions and human disease. The International Journal of Biochemistry & Cell Biology, 39(1), 44-84.
6. Kell, D. B., & Pretorius, E. (2014). Serum ferritin is an important inflammatory disease marker, as it is mainly a leakage product from damaged cells. Metallomics, 6(4), 748-773.
7. McClain, D. A., Abraham, D., Rogers, J., Brady, R., Gault, P., Ajioka, R., & Kushner, J. P. (2006). High prevalence of abnormal glucose homeostasis secondary to decreased insulin secretion in individuals with hereditary haemochromatosis. Diabetologia, 49(7), 1661-1669.
8. Brissot, P., Pietrangelo, A., Adams, P. C., de Graaff, B., McLaren, C. E., & Loréal, O. (2018). Haemochromatosis. Nature Reviews Disease Primers, 4(1), 1-21.
9. Connor, J. R., Lee, S. Y., HFE mutations and Alzheimer's disease. J Alzheimers Dis. 2006;10(2-3):267-76.
10. Iron Disorders Institute. (2010) H63D: The Other Mutation
11. Nasrullah et al. Cureus 14(11): e31840. DOI 10.7759/cureus.31840
12. Powell LW, Dixon JL, Ramm GA, et al. Screening for Hemochromatosis in Asymptomatic Subjects With or Without a Family History. Arch Intern Med. 2006;166(3):294–301. doi:10.1001/archinte.166.3.29
13. Anastasios Papadopoulos, Riku Honda, David Seideman, Alexandros Balaskas et al. (2021) Prevalence of Narcolepsy in Patients with H63D Syndrome. Sys Rev Pharm 2021; 12(9): 508-510. A multifaceted review journal in the field of pharmacy E-ISSN 0976-2779 P-ISSN 0975-8453.
14. Smith, Lucas, Seideman, David, Diamandis, Carolina. (2021). H63D: The Other Mutation (2021 Version) (1.4). Zenodo. https://doi.org/10.5281/zenodo.5676498
15. Carolina Diamandis, Jonathan Wilson, Olga Ivanova, et al. H63D syndrome (Oslo Syndrome) is clinically the iron sibling of Wilson's disease. Authorea. 06/2022. DOI: 10.22541/au.165459421.16231448/v1
16. Pratap U, Quinn S, Blizzard LB, Reid DW.Population-based study of cystic

fibrosis disease severity and hemochromatosis gene mutations. Respirology. 2010 Jan;15(1):141-9.
17. Jin F, Qu LS, Shen XZ. Association between C282Y and H63D mutations of the HFE gene with hepatocellular carcinoma in European populations: a meta-analysis. Gastroenterology. 2010 J Exp Clin Cancer Res. 2010 Mar 2;29:18. Mar;138(3):905-12.
18. Valenti L, Fracanzani AL, Bugianesi E, Dongiovanni P, Galmozzi E, Vanni E, Canavesi E, Lattuada E, Roviaro G, Marchesini G, Fargion S. HFE genotype, parenchymal iron accumulation, and liver fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology. 2010 Mar;138(3):905-12. doi: 10.1053/j.gastro.2009.11.013. Epub 2009 Nov 18. PMID: 19931264.
19. Sørensen S. et al.: H63D Syndrome Consortium 2020. Consensus Paper of the International H63D Research Consortium (English Edition)
20. Seideman, Adams, Kaufmann, et al. (2021): Incidence of a clinically relevant H63D syndrome in carriers of a homozygous mutation of HFE gene H63D. Research Square, May 2021, https://doi.org/10.21203/rs.3.rs-487488/v1
21. Pascal Wagner (2016) Oshtoran Syndrome. SCRIBD ePub
22. Davis, Benjamin, Levi, Daniel M., Gupta, Rahul, Zahedi, Hamed, Shirazi, Mohammad, & Smith, Samantha N. (2022). Oshtoran Syndrome meets Spider-Man: How a group of Iranian amateur researchers inadvertently influenced pop culture. https://doi.org/10.5281/zenodo.7109840
23. Adams, Jacob, Nathan, Simon, Feldman, Jo, Honda, Riku, Asgari, Ali, Ivanova, Olga, & Diamandis, Carolina. (2023). Management and multi-disciplinary approach in complex cases of PANS-H63D-Multisystemic Instability Syndrome. In Zenodo OpenAire: Vol. July 2023 (7.1, Number ePub). Zenodo. https://doi.org/10.5281/zenodo.8299513
24. Zafarian, Madjid. (2023). Congratulations for having discovered Oshtoran Syndrome a second time. In OpenAire: Vol. ePub (Number Sep 2023). Zenodo. https://doi.org/ 10.5281/zenodo.8320541
25. H63D, Research Consortium. (2023). The Imperative of Publishing Data on Rare Diseases like PANS-H63D-Multisystemic Instability Syndrome. Openaire, 09/23(ePub). https:// doi.org/10.5281/zenodo.83116
26. Feldman, Jo, Honda, Riku, Schneider, Katharina, Schmidt, Richard, & Tudor, Adrian. (2023). Oshtoran Syndrome aka Spider-Man's Disease or PANS-H63D-Instability- Syndrome: A rare illness amplified by pop culture and scientific perseverance. In Zenodo openAir: Vol. September 2023. Zenodo. https://doi.org/10.5281/zenodo.8322986
27. Younger DS. Pediatric neuropsychiatric disorders with motor and nonmotor phenomena. Handb Clin Neurol. 2023;196:367-387. doi: 10.1016/B978-0-323-98817-9.00028-4. PMID: 37620079.
28. Murphy TK, Gerardi DM, Leckman JF. Pediatric acute-onset neuropsychiatric syndrome. Psychiatr Clin North Am. 2014 Sep;37(3):353-74. doi: 10.1016/j.psc.2014.06.001. PMID: 25150567.
29. Murgia F, Gagliano A, Tanca MG, Or-Geva N, Hendren A, Carucci S, Pintor M, Cera F, Cossu F, Sotgiu S, Atzori L, Zuddas A. Metabolomic Characterization of Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS). Front Neurosci. 2021 May 28;15:645267.

doi: 10.3389/fnins.2021.645267. PMID: 34121984; PMCID: PMC8194687.
30. Sigra S, Hesselmark E, Bejerot S. Treatment of PANDAS and PANS: a systematic review. Neurosci Biobehav Rev. 2018 Mar;86:51-65. doi: 10.1016/j.neubiorev.2018.01.001. Epub 2018 Jan 6. PMID: 29309797.
31. Cooperstock MS, Swedo SE, Pasternack MS, Murphy TK. Clinical Management of Pediatric Acute-Onset Neuropsychiatric Syndrome: Part III-Treatment and Prevention of Infections. J Child Adolesc Psychopharmacol. 2017 Sep;27(7):594-606. doi: 10.1089/cap.2016.0151. Epub 2017 Jul 19. PMID: 36358106; PMCID: PMC9836684.
32. Calaprice D, Tona J, Parker-Athill EC, Murphy TK. A Survey of Pediatric Acute-Onset Neuropsychiatric Syndrome Characteristics and Course. J Child Adolesc Psychopharmacol. 2017 Sep;27(7):607-618. doi: 10.1089/cap.2016.0105. Epub 2017 Jan 31. PMID: 28140619.
33. Marazziti D, Mucci F, Fontenelle LF. Immune system and obsessive-compulsive disorder. Psychoneuroendocrinology. 2018 Jul;93:39-44. doi: 10.1016/j.psyneuen.2018.04.013. Epub 2018 Apr 13. PMID: 29689421.
34. Endres D, Pollak TA, Bechter K, Denzel D, Pitsch K, Nickel K, Runge K, Pankratz B, Klatzmann D, Tamouza R, Mallet L, Leboyer M, Prüss H, Voderholzer U, Cunningham JL; ECNP Network Immuno-NeuroPsychiatry; Domschke K, Tebartz van Elst L, Schiele MA. Immunological causes of obsessive-compulsive disorder: is it time for the concept of an "autoimmune OCD" subtype? Transl Psychiatry. 2022 Jan 10;12(1):5. doi: 10.1038/s41398-021-01700-4. PMID: 35013105; PMCID: PMC8744027.
35. Chang K, Frankovich J, Cooperstock M, Cunningham MW, Latimer ME, Murphy TK, Pasternack M, Thienemann M, Williams K, Walter J, Swedo SE; PANS Collaborative Consortium. Clinical evaluation of youth with pediatric acute-onset neuropsychiatric syndrome (PANS): recommendations from the 2013 PANS Consensus Conference. J Child Adolesc Psychopharmacol. 2015 Feb;25(1):3-13. doi: 10.1089/cap.2014.0084. Epub 2014 Oct 17. PMID: 25325534; PMCID: PMC4340805.
36. Bellanti JA. The PANDAS/PANS disorders. Is it time for more allergist-immunologists to get involved? Allergy Asthma Proc. 2023 Sep 1;44(5):296-305. doi: 10.2500/aap.2023.44.230029. PMID: 37641225.
37. Palma JA. Dysautonomia in the synucleinopathies: not just orthostatic hypotension. Clin Auton Res. 2019 Dec;29(6):547-548. doi: 10.1007/s10286-019-00645-5. Epub 2019 Oct 24. PMID: 31650378.
38. Richie M, Goss A, Jaradeh S. ANA Investigates Dysautonomia. Ann Neurol. 2022 Jan;91(1):21-22. doi: 10.1002/ana.26273. Epub 2021 Nov 29. PMID: 34787333.
39. Goldstein DS. Dysautonomia in Parkinson disease. Compr Physiol. 2014 Apr;4(2):805-26. doi: 10.1002/cphy.c130026. PMID: 24715569; PMCID: PMC4222515.
40. Kwaśniak-Butowska M, Dulski J, Pierzchlińska A, Białecka M, Wieczorek D, Sławek J. Cardiovascular dysautonomia and cognition in Parkinson's Disease - a possible relationship. Neurol Neurochir Pol. 2021;55(6):525-535. doi: 10.5603/PJNNS.a2021.0040. Epub 2021 May 26. PMID: 34037978.
41. Albanese A, Cocco A, Milani P, Lalli S, Palladini G. Parkinsonism and

dysautonomia: Multiple system atrophy? Parkinsonism Relat Disord. 2020 Aug;77:146-149. doi: 10.1016/j.parkreldis.2019.05.005. Epub 2019 May 3. PMID: 31097298.
42. Tezuka T, Okuzumi S, Nakashima C, Ide T, Imai S, Mitsuboshi S, Kuwahara Y, Takizawa T, Seki M, Minematsu N, Aragane N, Nakahara J, Hori S, Nakane S, Suzuki S. Dysautonomia associated with immune checkpoint inhibitors. J Neurol. 2023 Jul;270(7):3413-3423. doi: 10.1007/s00415-023-11667-5. Epub 2023 Mar 20. PMID: 36939931.
43. Burton JM, Morozova OM. Calming the Storm: Dysautonomia for the Pediatrician. Curr Probl Pediatr Adolesc Health Care. 2017 Jul;47(7):145-150. doi: 10.1016/j.cppeds.2017.06.009. Epub 2017 Jul 15. PMID: 28716515.
44. Lee, G. R., Boggs, D. R. (1983). Metal Metabolism in Hematologic Disorders. Grune & Stratton.
45. Cassidy, S. B., Allanson, J. E. (2011). Management of Genetic Syndromes. Wiley.
46. Hoffman, R., Benz, E. J., Silberstein, L. E., Heslop, H., Weitz, J., Anastasi, J. (2013). Hematology: Diagnosis and Treatment E-Book. Elsevier Health Sciences.
47. Unpublished data
48. Thiamine: Catalytic Mechanisms in Normal and Disease States. (2003). CRC Press.
49. Koene, S., Smeitink, J. A. M., Smeitink, J. A. M., Hirano, M. (2011). Mitochondrial Medicine: A Clinical Guideline. Khondrion.
50. Inborn Metabolic Diseases: Diagnosis and Treatment. (2013). Germany: Springer Berlin Heidelberg.
51. Thomas, A. (2009). Evaluation of Pyruvate Dehydrogenase Complex Activities in Muscle from South African Patients with Suspected Mitochondrial Disorders. (n.p.): North-West University, Potchefstroom Campus.
52. Meirleir, L. D. (2013). Pediatric Neurology Part III: Chapter 169. Disorders of Pyruvate Metabolism. Elsevier Science.
53. Mitochondrial Function and Dysfunction. (2003). Netherlands: Elsevier Science.
54. Multiple System Atrophy. (2014). Springer Vienna.

o

H63D Syndrome Research Consortium